Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition

AAPS Journal

Volumn 17, Issue 2, 2015, Pages 389-399

  Singh, Aman P ^a   Krzyzanski, Wojciech ^a   Martin, Steven W ^b   Weber, Gregory ^b   Betts, Alison ^b   Ahmad, Alaa ^b   Abraham, Anson ^b   Zutshi, Anup ^b   Lin, John ^c   Singh, Pratap ^b,d  

^a UNIVERSITY AT BUFFALO   (United States)

^b PFIZER INC   (United States)

^c Experimental Medicine   (United States)

^d Rinat Experimental Medicine ^*  (United States)

Author keywords

ADME of biologics; human translation; monoclonal antibodies; PK PD modeling; TMDD

Indexed keywords

MONOCLONAL ANTIBODY;

ANIMAL; BIOLOGICAL MODEL; HUMAN; MACACA FASCICULARIS; NONLINEAR SYSTEM; PRECLINICAL STUDY; PROCEDURES; SPECIES DIFFERENCE; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MACACA FASCICULARIS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; SPECIES SPECIFICITY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84940001922     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9690-8     Document Type: Article

References (32)

1. Rodrigues ME, Costa AR, Henriques M, Azeredo J, Oliveira R. Technological progresses in monoclonal antibody production systems. Biotechnol Prog. 2010;26(2):332–51. doi:10.1002/btpr.348.
2. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68. doi:10.1002/jps.20178.
3. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58. doi:10.1038/clpt.2008.170.
4. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24(1):23–39. doi:10.2165/11530560-000000000-00000.
5. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59. doi:10.2165/11535960-000000000-00000.
6. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924–33. doi:10.1056/NEJMoa054693.
7. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598–608. doi:10.1056/NEJMoa043980.
8. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–28. doi:10.1056/NEJMoa063842.
9. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991;8(11):1351–9. doi:10.1023/A:1015836720294.
10. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci. 2004;93(1):177–85. doi:10.1002/jps.10531.
11. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos. 2010;31(4):253–63. doi:10.1002/bdd.708.
12. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol. 2009;49(12):1382–402. doi:10.1177/0091270009337134.
13. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61–6. doi:10.4161/mabs.3.1.13799.
14. Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, et al. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet. 2011;26(4):423–30. doi:10.2133/dmpk.DMPK-11-RG-011.
15. Oitate M, Nakayama S, Ito T, Kurihara A, Okudaira N, Izumi T. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab Pharmacokinet. 2012;27(3):354–9.
16. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011;50(2):131–42. doi:10.2165/11537430-000000000-00000.
17. Kagan L, Abraham AK, Harrold JM, Mager DE. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res. 2010;27(5):920–32. doi:10.1007/s11095-010-0098-6.
18. Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther. 2012;341(3):702–8. doi:10.1124/jpet.112.191999.
19. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32. doi:10.1023/A:1014414520282.
20. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589–96. doi:10.1007/s11095-005-6650-0.
21. Lavielle M, Mentre F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn. 2007;34(2):229–49. doi:10.1007/s10928-006-9043-z.
22. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504. doi:10.1023/A:1012299115260.
23. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm. 1999;27(4):397–420. doi:10.1023/A:1020917122093.
24. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res. 2006;23(1):95–103. doi:10.1007/s11095-005-8814-3.
25. Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y, Stefanich E, et al. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthritis Res Ther. 2011;13(5):R177. doi:10.1186/ar3502.
26. Zheng Y, Scheerens H, Davis Jr JC, Deng R, Fischer SK, Woods C, et al. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther. 2011;89(2):283–90. doi:10.1038/clpt.2010.311.
27. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24(2):328–32.
28. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998;25(2):308–13.
29. Machy P, Truneh A. Differential half-life of major histocompatibility complex encoded class I molecules in T and B lymphoblasts. Mol Immunol. 1989;26(8):687–96. doi:10.1016/0161-5890(89)90027-8.
30. Truneh A, Machy P. Detection of very low receptor numbers on cells by flow cytometry using a sensitive staining method. Cytometry. 1987;8(6):562–7. doi:10.1002/cyto.990080605.
31. Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010;333(1):2–13. doi:10.1124/jpet.109.164129.
32. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1–2):81–8. doi:10.1016/S1359-6446(05)03638-X.